Pyruvate Kinase Deficiency research hub

A Study to Provide Access to Mitapivat for Participants Who Previously Participated in an Agios-Sponsored Mitapivat Study

This study allows patients who are already benefiting from a drug called mitapivat in a previous trial to continue taking it. It's for those with conditions like Pyruvate Kinase Deficiency, Sickle Cell Disease, or Thalassemia, to ensure they can keep receiving the treatment if their doctor believes it's helping them.